Swiss Medica is Title Sponsor of the National Fibromyalgia Association-Fibromyalgia Patient and Medical Education Conferences.

TORONTO -- Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce that it is the title sponsor of the National Fibromyalgia Association (NFA) - Fibromyalgia Patient and Medical Education Conference (FAME) (March 16-19) in Anaheim, California. FAME will bring together patients, physicians and medical researchers, and is expected to be the most comprehensive patient and medical education/research conference ever held to help people suffering with the chronic symptoms of fibromyalgia.

Swiss Medica in conjunction with the NFA is co-sponsoring the 2nd Annual "Leaders Against Pain" Advocacy and Media Training seminar. The two-day seminar will teach the participants how to work with the media and develop local advocacy programs to support efforts on behalf of people with fibromyalgia and other chronic pain illnesses. The seminar will also have a Q&A session with prominent journalists

"We are proud to participate in this milestone event with the NFA," said Grant Johnson, President and COO of Swiss Medica, manufacturers of the new O24 Fibromyalgia topical pain reliever. "This training seminar has all of the top influencers in the fibromyalgia community gathered in one location, this is the most important event we could attend to raise the awareness of O24 Fibromyalgia in the medical and patient communities."

O24 Fibromyalgia is a patented and clinically tested over-the-counter topical pain reliever for fibromyalgia. O24 Fibromyalgia is the first OTC or prescription product specifically for fibromyalgia that is available in national retailers was recently awarded the first NFA Seal of Approval. O24 Fibromyalgia is available nationally in the United States and Canada in leading pharmacies.

About The National Fibromyalgia Association (NFA)

The National Fibromyalgia Association (NFA) is the nationally-recognized leader in supporting fibromyalgia research, education, advocacy, and awareness. Founded in 1997, the NFA is the largest nonprofit (501(C)3) fibromyalgia organization in the United States. Its' mission is to develop and execute programs to improve the quality of life for people with fibromyalgia and overlapping conditions by increasing awareness of the public, the government, the media, and the medical community. It is estimated that each year, the NFA helps over 1 million people affected by fibromyalgia.

About Swiss Medica, Inc. :

Swiss Medica commercializes clinically tested, patented natural products that relieve chronic ailments. We grow our brands through focused distribution and marketing strategies. Swiss Medica's mission is to be a world leader in the commercialization of safe, effective chronic ailment products that improve quality of lives. Please visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used and recommended for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available over-the-counter throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest retailer.

Swiss Medica also distributes PMS Escape(R) which holds US Patent #'s 5760014 and 5612320. PMS Escape(R) is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to acceptance of Swiss Medica's products in Canada, the United States and other countries, risks related to international sales and purchases and potential foreign currency exchange fluctuations, acceptance of Swiss Medica's products, increased levels of competition, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Swiss Medica, Inc. (OTC Bulletin Board:SWME)